Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy and safety of two doses of NN-220 (somatropin) in short stature due to Noonan syndrome
2018-000750-22Phase 3
- Sponsor
- Novo Nordisk
- Start
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of somatropin in Noonan syndrome (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in height SDS.
02
Drugs
somatropin
03
Conditions
Noonan syndrome
Beyond the preview
Go deeper on 2018-000750-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000750-22.